VIVS Key Statistics, Chart & Performance
The current stock price of VIVS is 2.155 USD. In the past month the price decreased by -1.75%.
VIVS Latest News, Press Relases and Analysis
VIVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.6 | 410.65B | ||
| AMGN | AMGEN INC | 15.48 | 182.22B | ||
| GILD | GILEAD SCIENCES INC | 15.55 | 158.01B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.69 | 109.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.27 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 845.18 | 56.50B | ||
| INSM | INSMED INC | N/A | 44.01B | ||
| NTRA | NATERA INC | N/A | 32.77B | ||
| BIIB | BIOGEN INC | 10.89 | 26.73B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.28 | 21.83B | ||
| INCY | INCYTE CORP | 16.56 | 20.76B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About VIVS
Company Profile
VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 13 full-time employees. The company went IPO on 2013-08-02. The firm offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The firm offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. The company uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The firm's 3D human tissue platform is multifaceted. The firm has expertise in 3D organoids, such as spheroids, and has made advances in proprietary cell culture techniques including ratios, components and conditions.
Company Info
VIVOSIM LABS INC
11555 Sorrento Valley Road, Suite 100
San Diego CALIFORNIA US
Employees: 13
Phone: 18582241000
VIVOSIM LABS INC / VIVS FAQ
What does VIVOSIM LABS INC do?
VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 13 full-time employees. The company went IPO on 2013-08-02. The firm offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The firm offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. The company uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The firm's 3D human tissue platform is multifaceted. The firm has expertise in 3D organoids, such as spheroids, and has made advances in proprietary cell culture techniques including ratios, components and conditions.
What is the current price of VIVS stock?
The current stock price of VIVS is 2.155 USD. The price decreased by -4.22% in the last trading session.
Does VIVS stock pay dividends?
VIVS does not pay a dividend.
How is the ChartMill rating for VIVOSIM LABS INC?
VIVS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for VIVS stock?
The Revenue of VIVOSIM LABS INC (VIVS) is expected to grow by 18.24% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does VIVOSIM LABS INC have?
VIVOSIM LABS INC (VIVS) currently has 13 employees.
Can you provide the short interest for VIVS stock?
The outstanding short interest for VIVOSIM LABS INC (VIVS) is 19.31% of its float.
VIVS Technical Analysis
VIVS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to VIVS. While VIVS has a great health rating, there are worries on its profitability.
VIVS Financial Highlights
Over the last trailing twelve months VIVS reported a non-GAAP Earnings per Share(EPS) of 2.75. The EPS increased by 297.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.59% | ||
| ROE | -20.83% | ||
| Debt/Equity | 0 |
VIVS Forecast & Estimates
For the next year, analysts expect an EPS growth of 2.6% and a revenue growth 18.24% for VIVS